The FDA approved Endomagnetics' magnetic tracer injection and detection system for guiding lymph node biopsies in patients with breast cancer undergoing mastectomy. In the procedure, the clinician injects a solution of dextran-coated iron oxide magnetic nanoparticles (Magtrace) in the viscinity of the tumour or the areola, as is done typically with dye or radioactive tracers. The Magtrace then clears along lymphatic vessels and labels the sentine...

Endomag has announced that it has received 510(k) clearance from the FDA to extend the indication of its Magseed magnetic marker to include both the marking of soft tissue and long-term implantation. The Magseed marker has already been used in thousands of lesion localisations for breast cancer. This FDA clearance makes it the world’s only wire-free localisation device that can be implanted into any soft tissue.

Endomag has announced that it has received CE Mark approval for Magseed, a minimally invasive breast marker used to accurately guide surgeons during breast cancer removal. Magseed will be distributed throughout EMEA by Sysmex, as part of a new 5-year distribution deal for the Sentimag surgical guidance platform. Magseed allows a radiologist to accurately mark the tumour site with a seed, smaller than a grain of rice, up to 30 days before sur...

Endomagnetics has announced that it has raised a further £2m to support its pivotal US clinical trial and the launch of a new cancer marker product in 2015. The funds will also support market development beyond EMEA and Australasia, where the company is already established, and will accelerate product development beyond the initial breast cancer application.

Endomagnetics announce the acquisition of the ACT portfolio and related assets from Actium Biosystems, LLC.  This move extends Endomagnetics’ oncology platform from diagnostics into therapeutics while maintaining synergies with its magnetic nanoparticle technology.

Endomagnetics has achieved certification to an international quality standard. Endomagnetics’ Quality Management System has been evaluated and certified by BSI as meeting the standards of ISO 13485:2003.

Endomagnetics has raised additional funding, taking the sum raised in the last few months to £1.8 million. The Company has also announced a move to Cambridge as it expands its operations. Endomagnetics is a spin out from University College London (UCL), and is developing advanced magnetic sensors originally developed at UCL and at the University of Houston.

Endomagnetics has achieved CE approval for the sale of its magnetic tracer material, branded Sienna+. The injectable tracer is used in combination with the ultra-sensitive SentiMag instrument in sentinel lymph node biopsy (SLNB), currently the standard of care in tracking the spread of breast cancer.

Endomagnetics and one of its founders has picked up a major accolade by being recognised in the Science Business Academic Excellence Awards (ACES). The company picked up the Life Sciences Award, given by the distinguished panel of judges to the most successful university spin-out company. Endomagnetics is developing advanced magnetic sensing technology for use in breast cancer staging, based on technology developed between University College Lo...

Cambridge company Endomagnetics is receiving enquiries from across the world after it featured on the BBC World Horizons programme recently. The Horizons series features companies and technologies that have the potential to address some of the planet’s most pressing challenges.